Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19 (NCT04556864) | Clinical Trial Compass
UnknownNot Applicable
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
Spain67 participantsStarted 2020-10-01
Plain-language summary
The aim of the present work is to describe the hemodynamic effects shown in patients with ARDS secondary to SARS-CoV-2 infection
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients over 18 years old.
* Patients that are classified as a "confirmed case" according to criteria established by the Spanish Ministry of Health in its Technical Document updated on March 31, 2020. This defines a "confirmed case" as a case that meets laboratory criteria (Positive PCR test for any of the SARS-CoV-2 genes).
* Patients admitted to ICU.
* Presence of Kirby index (PaFi) less than or equal to 300 mm Hg, with PEEP or CPAP greater than or equal to 5 cmH2O.
* Need for radial artery cannulation for hemodynamic monitoring and/or repeated monitoring of blood gases at the discretion of the responsible physician.
* Patients who agree (or a representative of the patient if sedated) to participate in study and who provide written informed consent.
Exclusion Criteria:
* Patients being treated with veno-venous or veno-arterial ECMO
* Patient with therapeutic restrictions due to life support
* Patient who presents a complication that requires surgical intervention.